Evidence map›Paper›PMID 39862605›Full record

ReviewCurrent opinion in genetics & development2025

Rewiring cancer: 3D genome determinants of cancer hallmarks.

Maria E Amodeo, Christine E Eyler, Sarah E Johnstone

Abstract readReview
In one paragraph

Review in Current opinion in genetics & development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. The Biological Function of Genome Organization.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Maria E AmodeoDepartment of Pathology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute, Cambridge, MA, USA.
Christine E EylerDepartment of Radiation Oncology, Duke University School of Medicine, Durham, NC, USA. Electronic address: christine.eyler@duke.edu.
Sarah E JohnstoneDepartment of Pathology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute, Cambridge, MA, USA; Department of Pathology, Harvard Medical School, Boston, MA, USA. Electronic address: sarah_johnstone@dfci.harvard.edu.

Funding

Harnessing treatment-induced tumor evolution and collateral sensitivities using a human rectal cancer co-clinical platformK08CA263300 · NCI · DUKE UNIVERSITY · PI Christine Elissa Eyler · 2022 to 2026
$1.2M
Elucidating the impact of DNA hypomethylation on genome organization and anti-tumor transcriptional programs.K08CA259623 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JOHNSTONE, SARAH E · 2021 to 2025
$976k
NCI NIH HHS K08 CA259623NCI NIH HHS K08 CA263300
6 · The paper itself

Abstract

In modern cancer biology, Hanahan and Weinberg's classic depiction of the Hallmarks of Cancer serves as a heuristic for understanding malignant phenotypes [1]. Genetic determinants of these phenotypes promote cancer induction and progression, and these mutations drive current approaches to understanding and treating cancer. Meanwhile, for over a century, pathologists have noted that profound alterations of nuclear structure accompany transformation, integrating these changes into diagnostic classifications (Figure 1). Nevertheless, the relationship of nuclear organization to malignant phenotypes has lagged. Recent advances yield profound insight into the 3D genome's relationship with cancer phenotypes, suggesting that spatial genome organization influences many, if not all, of these malignant features. Here, we highlight recent discoveries elucidating connections between 3D genome organization and cancer phenotypes.

Indexed as

Genome, HumanNeoplasmsCell NucleusHumansMutationPhenotype

Identifiers

PMID39862605
PMCPMC11867856

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.